Abdul Hafeez has completed Ph.D. in Pharmacy (Pharmaceutics) and have 08 year experience in academic and research as Assistant professor currently working in Glocal University During academic job involve in various academic activities. And having good instrument handling experience. scholarly interests range widely, from the development of gastro retentive drug delivery systems, Nano drug delivery, buccal drug delivery systems, micro particulate drug delivery systems etc. He has published more than 20 papers in reputed journals with impact factors recently published paper in scientific reports. Published 04 book chapters (01 under communication).. He attended many national and internationals conferences. Recently he has given poster presentation in DUPHAT 2018 dubai as well as Asia Pharma Conference in Kuala Lumpur, Malaysia in July, 2016. He is a member of reputed pharmaceutical societies like Association of Pharmaceutical Teachers of India (APTI) and Indian Pharmacy Graduate Association (IPGA).

Dacarbazine (DZ) is single drug approved by US-FDA for the treatment of a type of skin cancer melanoma., slow response rate with severe toxicity which limits its market potential. In view this study designed for formulation, characterization and pharmacological evaluation of dacarbazine laden nanocream (DZC) for the treatment of melanoma. DZC prepared by oil-in-water emulsion technique by using DZP. Dacarbazine nanoparticle and its cream were characterized for shape size of particle, drug loading capacity, nanoencapsulation efficacy, zeta potential, Transmission Electron Microscopy (TEM), pH value, spreadability and viscosity, in vitro drug releasing capacity and its cytotoxic effect by using MTT assay. The particle size of DZNP and DZNC was 16.3±8.1 nm and 16.9±7.8 nm respectively. pH value and spreadability of nanoparticle cream were found to be 6.7±0.14 g cm/sec and 55.23±3.13 g cm/sec respectively. Nanoencapsulation efficiency and Drug loading capacity were 67.4±3.5% and 6.73 mg/10 mg respectively. From above results, it can be concluded that DZC can be effectively utilized for the treatment of melanoma.

Dr. Zaghloul is an Associate Professor of Pharmaceutics at Faculty of Pharmacy, Kuwait University. He obtained his M.Sc. and Ph.D. degrees from Faculty of Pharmacy, Al-Azhar University, Egypt. In 1999, he joined school of Pharmacy at Texas Tech University as a Postdoctoral Research Fellow. In 2003, he joined Kuwait University. Dr. Zaghloul has published more than 30 research papers and review articles in perreviewed international journals and presented more than 50 oral and poster presentation. His research interests are design and evaluation of

different drug delivery systems as well as evaluation of critical process and formulation variables by optimization procedures and neural networks.

Epilepsy is a major public health concern with an estimated 4.7 million people in the Eastern Mediterranean Region. Although, the occurrence of epilepsy is uncertain, it is more likely to occur in young children or people above 65 years old. Levetiracetam (LEV) is the most frequently prescribed anti-epileptic drug for children with less side effects. Unfortunately, it has intense bitter taste and extensive liver metabolism. In this study we aimed to develop paediatric rectal suppositories of LEV to improve bioavailability and patient compliance. Suppository fatty bases (Witepsol® and Massa®; different grades) and hydrophilic bases (PEG,different grades with different proportions) were used to prepare 1 gm rectal suppositories each containing 250 mg LEV by fusion method. The formulations were characterized for weight uniformity, mechanical strength, melting time, penetration time, content uniformity, extraction efficiency and drug release in distilled water using UV spectrophotometry at 209 nm. The results indicated that the preparation method produced suppositories elegant in shape and free of physical deformities. The average melting time for fatty suppositories was 7.5 min, the mechanical strength ranged between 6-8 kg/cm and the penetration time ranged between

5.5-7.5 min. For hydrophilic bases, the average disintegration time, mechanical strength and penetration time were 6 min, 7 kg/cm and 6.5 min, respectively. The drug could be efficiently extracted from the bases. PEG 1000/4000; 96/4 base showed the best results of drug release (100%) followed by PEG 1000/6000; 50/50(98%) followed by Massa E fatty base (86.1%) after 30 min of dissolution time. In conclusion, LEV rectal suppositories were successfully prepared and characterized and drug incorporated in PEG hydrophilic bases

could be used as a potential alternative to the oral tablets. Extra work will be done to get the optimized formulation that will be tested later for in vivo availability on animal and/or human volunteers.

Yavuz Selim Silay is the Co-Founder & CEO of MaQasid Angel Investors Network (MAIN) and Chairman of Istanbul Consulting Group. He is currently the Co-Founder of BioCube İstanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Archem Diagnostics. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and Director of Avcılar Hospital R&D Center. Previously he has worked as the Market Access & Health Policy Director for AIFD in Turkey. He has previously worked as the Vice President of Ipsen Pharmaceutical and Director of Teva Pharmaceutical in USA managing large clinical trials as well as Investigator initiated trials and developing relationships with key opinion leaders. He was the Associate Director at KV Pharmaceuticals and Director in Clinical Development Department at Forest Laboratories. He has earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He has completed a Clinical Internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis.

Large pharmaceutical, biotech and medical device companies are constantly evaluating how to work with universities and startup companies and utilize. Istanbul Consulting Group recently worked with Istanbul Aydın University to establish a thematic program in Healthcare Bioentrepreneurship which has taken the road with the slogan of "Towards a Bright Future", at the brightest spots of business life. Istanbul Aydın University is a city and campus university located in the center of Istanbul with its experienced academic staff who

have gained a reputation for their scientific studies globally. At BioCube Ä°stanbul several healthcare startup companies are flourishing thanks to the coordination of technology transfer and project management offices

successful coordination on innovation management with all key stakeholders. To gain these critical insights for thematic management of healthcare bioentrepreneurship and innovation track in universities and how

to accelerate innovations in order to improve healthcare. We seek to empower entrepreneur academicians,doctors, other healthcare providers and with the information, resources, connections and experience they need to commercialize their ideas, inventions and discoveries. Current trends in innovation management in medicine in a university setting and the BioCube Istanbul Bioentrepreneurship and Innovation Center as a global case for USA, Europe, Turkey and emerging markets will be provided with unique cases. Dr. Yavuz Selim Silay a global physician leader and seasoned expert in Healthcare Innovation, Physician Entrepreneurship, Government engagement, Commercial Diplomacy, Corporate Communications, Government affairs & Medical Affairs will discuss how BioCube Ä°stanbul has been established and current engagements with academicians venture capital and angel investment networks for commercializing healthcare technologies will be discussed